Across TCGA pan-cancer cohorts, HCG9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HCG9 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HCG9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HCG9 expression acts as an unfavorable survival marker.

BLCA and ESCA are the cancer types where HCG9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.025	0.626	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: HCG9 tumor-vs-normal RNA expression · all HCG9 data types